Imipramine in the treatment of social phobia

We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical psychopharmacology 1998-04, Vol.18 (2), p.132-135
Hauptverfasser:	SIMPSON, H. B, SCHNEIER, F. R, CAMPEAS, R. B, MARSHALL, R. D, FALLON, B. A, DAVIES, S, KLEIN, D. F, LIEBOWITZ, M. R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antidepressive Agents, Tricyclic - adverse effects Antidepressive Agents, Tricyclic - therapeutic use Biological and medical sciences Female Humans Imipramine - adverse effects Imipramine - therapeutic use Male Medical sciences Middle Aged Neuropharmacology Pharmacology. Drug treatments Phobic Disorders - drug therapy Phobic Disorders - psychology Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Single-Blind Method
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, respectively; the overall response rate (based on the Clinical Global Impression Scale of 1 or 2, very much or much improved) was 20% (3/15) and 22% (2/9), respectively. The results from this open trial do not support the efficacy of imipramine as a treatment for social phobia.
ISSN:	0271-0749 1533-712X
DOI:	10.1097/00004714-199804000-00005